» Articles » PMID: 26261733

Primary Biliary Cirrhosis: From Bench to Bedside

Overview
Date 2015 Aug 12
PMID 26261733
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Primary biliary cirrhosis (PBC) is a chronic non-suppurative destructive intrahepatic cholangitis leading to cirrhosis after a protractive non cirrhotic stage. The etiology and pathogenesis are largely unknown and autoimmne mechanisms have been implicated to explain the pathological lesions. Many epitopes and autoantigens have been reported as crucial in the pathophysiology of the disease and T and B cells abnormalities have been described, the exact pathways leading to the destruction of small intrahepatic ductules are mostly speculative. In this review we examined the various epidemiologal and geoepidemiological data as well as the complex pathogenetic aspects of this disease, focusing on recent in vivo and in vitro studies in this field. Initiation and progression of PBC is believed to be a multifactorial process with strong infuences from the patient's genetic background and by various environmental factors. The role of innate and adaptive immunity, including cytokines, chemokines, macrophages and the involvement of apoptosis and reactive oxygen species are outlined in detailed. The current pathogenetic aspects are presented and a novel pathogenetic theory unifying the accumulated clinical information with in vitro and in vivo data is formulated. A review of clinical manifestations and immunological and pathological diagnosis was presented. Treatment modalities, including the multiple mechanisms of action of ursodeoxycholate were finally discussed.

Citing Articles

The clinical value of the monocyte to high-density lipoprotein cholesterol ratio and alkaline phosphatase-to-platelet ratio in primary biliary cholangitis.

Lao Y, Li X, Zhou W, Zhu H, Jiang Y, Li S Medicine (Baltimore). 2023; 102(41):e35454.

PMID: 37832129 PMC: 10578697. DOI: 10.1097/MD.0000000000035454.


Mesenchymal Stem Cells as New Therapeutic Agents for the Treatment of Primary Biliary Cholangitis.

Arsenijevic A, Harrell C, Fellabaum C, Volarevic V Anal Cell Pathol (Amst). 2018; 2017:7492836.

PMID: 29410945 PMC: 5749170. DOI: 10.1155/2017/7492836.


Cutaneous Metastasis due to Breast Cancer in a Patient with Primary Biliary Cirrhosis: A Case Report.

Kamaraju S, Depke J, Povletich J, Currey A, Weil E Case Rep Oncol. 2016; 9(3):718-725.

PMID: 27920708 PMC: 5126598. DOI: 10.1159/000452145.

References
1.
Tsuda M, Moritoki Y, Lian Z, Zhang W, Yoshida K, Wakabayashi K . Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2011; 55(2):512-21. DOI: 10.1002/hep.24748. View

2.
Prieto J, Garcia N, Marti-Climent J, Penuelas I, Richter J, Medina J . Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology. 1999; 117(1):167-72. DOI: 10.1016/s0016-5085(99)70564-0. View

3.
Abu-Mouch S, Selmi C, Benson G, Kenny T, Invernizzi P, Zuin M . Geographic clusters of primary biliary cirrhosis. Clin Dev Immunol. 2004; 10(2-4):127-31. PMC: 2485422. DOI: 10.1080/10446670310001626526. View

4.
Poupon R, Chretien Y, Poupon R, Ballet F, Calmus Y, DARNIS F . Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet. 1987; 1(8537):834-6. DOI: 10.1016/s0140-6736(87)91610-2. View

5.
Goulis J, Leandro G, Burroughs A . Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999; 354(9184):1053-60. DOI: 10.1016/S0140-6736(98)11293-X. View